Category: Guest content

After Myriad Oral Argument, Supreme Court Set to Decide Patentability of Isolated Human DNA Molecules

This is a guest post by Morrison & Foerster‘s  Marc A. Hearron, James J. Mullen, III and Matthew I. Kreeger. Do you have a response to this post? Sound off  in the comments section below. The Supreme Court of the United States recently heard oral argument in Association for Molecular Pathology v. Myriad Genetics, Inc. (No. 12-398) to […]



ISO a Scientific Revolution in Cancer Research

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Even if you have never heard of Thomas Kuhn, your thinking about science has most likely been effected by his theory of what causes paradigm shifts. Over 50 years […]



Will the UK be the Goose that Lays The Golden Access?

This guest post is from the BiotechBlog Intern,  Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. This month sees the introduction of the UK’s Open Access policy as recommended by the government-commissioned Finch Report into […]



A Long Road to an Informed Public Opinion

This guest post is from the BiotechBlog Intern,  Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. Bioethics in the public eye has been recognised as an integral part of modern biology research for a while […]



VC Biotech Funding: Perception and Reality

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. VCs are starting to talk again about the ‘perception’ of scarce funding for early stage bio-pharma: At the New Paradigms meeting (a satellite of JPM Conference), a panel I […]



Has Bio-Pharma Forgotten to Fail Early?

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below.  When I started working for PhRMA nearly 15 years ago, the mantra was “Fail early, Fail cheap.” Given the exponentially increased cost of advancing compounds pre-clinical into clinical research […]



Is the Clinical Research Enterprise in Decline?

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. It looks like the ‘new normal’ is not just for biotechnology startups and SME pharma companies  – the CROs (and other vendors) who previously benefited from better R&D funding streams also […]



The FDA’s modernisation of its bioprocess regulation

This is a guest post from the BiotechBlog Intern,  Fintan Burke. Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. It has now been more than a year since the FDA published a welcomed revision of the 1987 […]



Mark Levin, Third Rock Ventures: Personalized Medicine Needs Teamwork and Collaboration

Mark Levin, Third Rock Ventures: Personalized Medicine Needs Teamwork and Collaboration

For Third Rock Ventures' Mark Levin, personalized medicine is nothing new. Instead, he sees the history of pharma as a gradual homing in on the roots of dise…



Lung Cancer Early Detection 2.wmv

Lung Cancer Early Detection 2.wmv

Part 2 of 2. Social media is becoming an important gateway to patients and consumers for biotechnology companies wishing to commercialize without the major investment required for a sales force. Greg Stanley, Chief …



%d bloggers like this: